Grant: Operating Grant: COVID-19 - Therapeutics
University of Ottawa
$415,686.00
Drug repurposing for the rapid development and evaluation of SARS-CoV-2 antivirals
FY 2019-20
Summary
The initial symptoms of COVID-19 are fever, shortness of breath and a dry cough. For some patients, the disease progresses to pneumonia as the infection spreads to the lung and leads severe inflammation. These severe symptoms can cause difficulties for the lungs to oxygenate the blood and can lead to death. There are currently no antivirals against SARS-CoV2, the causative agent of COVID-19, and development of new molecules can take years to reach patients. As the COVID-19 epidemic is progressing rapidly, the need for antiviral therapy is urgent. Therefore, our goal is to use our current arsenal of approved drugs already tested for their safety and used in the clinic for various conditions and repurpose them to treat COVID-19. In this rapid response grant, we propose to identify drugs with activity against SARS-CoV2 in vitro and in vivo and contribute to the global COVID-19 response and provide a therapeutic option for patients developing life-threatening disease.
Department
Program
Operating Grant: COVID-19 - Therapeutics
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
422711
Name
Côté Marceline
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canadian 2019 Novel Coronavirus (2019-nCoV) Rapid Research
Projecttitle
Drug repurposing for the rapid development and evaluation of SARS-CoV-2 antivirals
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$415,686
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 - Therapeutics
Keyworddelim
Coronaviruses; Drug Repurposing; High-Throughput Screening; Mouse Model; Sars-Cov; Sars-Cov2; Viral Entry
Abstract
The initial symptoms of COVID-19 are fever, shortness of breath and a dry cough. For some patients, the disease progresses to pneumonia as the infection spreads to the lung and leads severe inflammation. These severe symptoms can cause difficulties for the lungs to oxygenate the blood and can lead to death. There are currently no antivirals against SARS-CoV2, the causative agent of COVID-19, and development of new molecules can take years to reach patients. As the COVID-19 epidemic is progressing rapidly, the need for antiviral therapy is urgent. Therefore, our goal is to use our current arsenal of approved drugs already tested for their safety and used in the clinic for various conditions and repurpose them to treat COVID-19. In this rapid response grant, we propose to identify drugs with activity against SARS-CoV2 in vitro and in vivo and contribute to the global COVID-19 response and provide a therapeutic option for patients developing life-threatening disease.
Competitiondate
202002
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Côté, Marceline; Giguere, Patrick M; Kobasa, Darwyn
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $415,686~ $0~
